barriers to glp-1 medication prescription ➡️ Authors of a report in @JAADjournals investigated potential associations between telogen effluvium (TE) and treatment for weight loss. Patients with a BMI of ≥30 without diabetes were included in the CHOP doctors identify barriers to
Description
Effectiveness of group medical visits for improving diabetes care: a systematic review and meta-analysis

Any reliance on the information in this article is at the reader's own risk

Europe Prescription Drug Market Trends 3.1.3

What is the best strategy for improving male fertility with GLP-1s

The risks of diarrhea was significantly higher for JNJ-64565111, Exenatide, Liraglutide, Orforglipron and Tirzepatide than for placebo, with Orforglipron having an RR of 5.56

But not all of that weight is fat
